DGAP-News: WILEX AG has been selected to give several presentations at ASCO

DGAP-News: WILEX AG / Key word(s): Research Update
WILEX AG has been selected to give several presentations at ASCO

11.04.2013 / 06:50

---------------------------------------------------------------------

PRESS RELEASE

WILEX has been selected to give several presentations at ASCO

Munich, Germany, 11 April 2013 - WILEX AG (ISIN DE0006614720 / WL6 / FSE)
today announced that scientific findings from clinical trials which were
conducted by WILEX and/or in cooperation with other organisations will be
presented at the Annual Meeting of the American Society of Clinical
Oncology (ASCO, 31 May - 4 June 2013) in Chicago.

- RENCAREX(R): Phase III ARISER trial in the adjuvant therapy for ccRCC
and particularly the efficacy of RENCAREX(R) in the subgroup of
patients with high CAIX

- MESUPRON(R): Phase II study in first-line HER2-negative metastatic
breast cancer treatment in combination with Capecitabine

- HER2/neu ELISA: Meta-analysis of the prognostic value of serum
HER2/neu levels in breast cancer patients

- CAIX and TIMP-1 ELISA: Elevated pretreatment serum biomarkers and
correlation with progression-free (PFS) and overall survival (OS) in
first-line Herceptin(R) treated metastatic breast cancer

The schedules for the presentations will be published on our website as
soon as they are made public.

There will be also an abstract presentation at the AUA 2013 Annual Meeting
of the American Urological Association (4 - 8 May 2013) in San Diego, CA,
during the Late-Breaking Science Forum on 7 May 2013, 01:00 pm - 02:30 pm
local time on the following topic:

- CAIX Score: Predicts Recurrence and Survival for High-Risk,
Non-Metastatic renal cell cancer patients

Dr Paul Bevan, Head of R&D and member of the Executive Management Board of
WILEX AG, said: 'We and our clinical trial partners and collaborators are
delighted to have the opportunity to present the data of several projects
at these important scientific conferences.'

About WILEX
WILEX AG is a biopharmaceutical company based in Munich, Germany. Focused
on oncology, the Company develops diagnostic and therapeutic product
candidates for the specific detection and targeted treatment of various
types of cancer. In the field of therapeutics, WILEX develops small
molecules (MESUPRON(R) two Phase IIa trials completed, WX-554 in Phase
Ib/II and WX-037 in preclinical development). In the field of diagnostics,
REDECTANE(R) is an antibody-based imaging in vivo diagnostic agent that is
currently in a Phase III programme. The Company also has a portfolio of
research use only tests and in vitro diagnostic agents that are marketed
via its US subsidiary WILEX Inc. in Cambridge, MA, under the brand Oncogene
Science. WILEX's subsidiary Heidelberg Pharma GmbH offers preclinical
contract research services and a highly promising antibody drug conjugate
(ADC) technology platform. The business model of WILEX comprises research
and product development as well as the commercialisation of its activities.
WILEX's customers and partners include leading international pharmaceutical
companies.

Website: http://www.WILEX.com, ISIN DE0006614720 / WKN 661472 / Symbol WL6.

Contact
Katja Arnold (CIRO)
Corporate Communications
WILEX AG
Grillparzerstr. 10
81675 Munich, Germany
Tel.: +49 (0)89-41 31 38-126
Fax: +49 (0)89-41 31 38-99
Email: investors@wilex.com

This communication contains certain forward-looking statements relating to
the Company's business, which can be identified by the use of
forward-looking terminology such as 'estimates', 'believes', 'expects',
'may', 'will', 'should', 'future', 'potential' or similar expressions or by
a general discussion of the Company's strategy, plans or intentions. Such
forward-looking statements involve known and unknown risks, uncertainties
and other factors, which may cause our actual results of operations,
financial position, earnings, achievements, or industry results, to be
materially different from any future results, earnings or achievements
expressed or implied by such forward-looking statements. Given these
uncertainties, prospective investors and partners are cautioned not to
place undue reliance on such forward-looking statements. We disclaim any
obligation to update any such forward- looking statements to reflect future
events or developments.

End of Corporate News

---------------------------------------------------------------------

11.04.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------

Language: English
Company: WILEX AG
Grillparzerstr. 10
81675 München
Germany
Phone: +49 (0)89 41 31 38 - 0
Fax: +49 (0)89 41 31 38 - 99
E-mail: info@wilex.com
Internet: www.wilex.com
ISIN: DE0006614720
WKN: 661472
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, München, Stuttgart

End of News DGAP News-Service
---------------------------------------------------------------------
206761 11.04.2013